The gut microbiome dysbiosis and regulation by fecal microbiota transplantation: umbrella review
Frontiers in Microbiology · 03.11.2023 · 14
DOI: 10.3389/fmicb.2023.1286429 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Microbiology, online erschienen am 03.11.2023. Verfasst von Xianzhuo Zhang und 19 weiteren Autor:innen. Beteiligte Einrichtung: The First School of Clinical Medicine, Lanzhou University, Lanzhou, China. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Gut microbiome dysbiosis has been implicated in various gastrointestinal and extra-gastrointestinal diseases, but evidence on the efficacy and safety of fecal microbiota transplantation (FMT) for therapeutic indications remains unclear.
Methods
The gutMDisorder database was used to summarize the associations between gut microbiome dysbiosis and diseases. We performed an umbrella review of published meta-analyses to determine the evidence synthesis on the efficacy and safety of FMT in treating various diseases. Our study was registered in PROSPERO (CRD42022301226).
Results
Gut microbiome dysbiosis was associated with 117 gastrointestinal and extra-gastrointestinal. Colorectal cancer was associated with 92 dysbiosis. Dysbiosis involving Firmicutes (phylum) was associated with 34 diseases. We identified 62 published meta-analyses of FMT. FMT was found to be effective for 13 diseases, with a 95.56% cure rate (95% CI: 93.88–97.05%) for recurrent Chloridoids difficile infection (rCDI). Evidence was high quality for rCDI and moderate to high quality for ulcerative colitis and Crohn’s disease but low to very low quality for other diseases.
Conclusion
Gut microbiome dysbiosis may be implicated in numerous diseases. Substantial evidence suggests FMT improves clinical outcomes for certain indications, but evidence quality varies greatly depending on the specific indication, route of administration, frequency of instillation, fecal preparation, and donor type. This variability should inform clinical, policy, and implementation decisions regarding FMT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
- Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
- Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, China.
- The Second Clinical Medical College, Lanzhou University, Lanzhou, China.
- Department of Pharmacy, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Radiology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China.
Zitieren
APA
Zhang, X., Luo, X., Tian, L., Yue, P., Li, M., Liu, K., Zhu, D., Huang, C., Shi, Q., Yang, L., Xia, Z., Zhao, J., Ma, Z., Li, J., Leung, J. W., Lin, Y., Yuan, J., Meng, W., Li, X., & Chen, Y. (2023). The gut microbiome dysbiosis and regulation by fecal microbiota transplantation: umbrella review. Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1286429
Vancouver
Zhang X, Luo X, Tian L, Yue P, Li M, Liu K, et al. The gut microbiome dysbiosis and regulation by fecal microbiota transplantation: umbrella review. Frontiers in Microbiology. 2023;14. doi:10.3389/fmicb.2023.1286429
BibTeX
@article{Zhang2023,
author = {Zhang, Xianzhuo and Luo, Xufei and Tian, Liang and Yue, Ping and Li, Mengyao and Liu, Kefeng and Zhu, Daoming and Huang, Chongfei and Shi, Qianling and Yang, Liping and Xia, Zhili and Zhao, Jinyu and Ma, Zelong and Li, Jianlong and Leung, Joseph W and Lin, Yanyan and Yuan, Jinqiu and Meng, Wenbo and Li, Xun and Chen, Yaolong},
title = {The gut microbiome dysbiosis and regulation by fecal microbiota transplantation: umbrella review},
journal = {Frontiers in Microbiology},
year = {2023},
volume = {14},
doi = {10.3389/fmicb.2023.1286429}
}
EUVIMED